ArticleScientific reports2022

Dipeptidylpeptidase (DPP)-4 inhibitor therapy increases circulating levels of anti-inflammatory soluble frizzle receptor protein (sFRP)-5 which is decreased in severe COVID-19 disease.

Juliane Brandes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.